Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT07629245RecruitingPhase 1/Phase 2
Cell therapy for Crohn's disease fistulas after prior treatment
This trial tests whether injecting your own fat-derived cells combined with a skin graft can heal anal fistulas (abnormal passages near the anus) that didn't respond to or came back after a previous cell therapy study. You must have already participated in the ADICROHN-2 study.
MarseilleAges 18 years+ - NCT07635056RecruitingPhase 2
Natural killer cells for hard-to-treat neuroblastoma
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Cincinnati, OhioAges 1–39 - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT07652632Recruiting
Regenerative endoscopy for hard-to-treat Crohn's fistulas
This trial tests a new, less invasive procedure called regenerative endoscopy to repair complex fistulas in people with Crohn's disease. It's for those who haven't gotten better with standard treatments like biologics or surgery.
Hyderabad, TelanganaAges 18–65 - NCT07661095RecruitingPhase 1
Study of CRD3874-SI for relapsed or refractory AML
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
Basking Ridge, New JerseyAges 18 years+ - NCT07567274Enrolling by invitationPhase 2
DMSO Therapy for Ringing in Ears After COVID
This trial tests a combination therapy using DMSO (a chemical that penetrates tissues) mixed with several medications to treat persistent ringing in the ears (tinnitus) that developed or worsened after COVID-19 infection or vaccination. If you have bothersome tinnitus linked to long COVID or vaccine injury and haven't responded to previous treatments, this study may help.
Ithaca, New YorkAges 18–70 - NCT07528079Enrolling by invitation
Personalized Chemotherapy for Children with Advanced Soft Tissue Tumors
This trial uses lab-grown tumor samples from your child to test which chemotherapy drugs work best for their specific cancer. The goal is to find the most effective treatment by testing medicines on their tumor cells before giving them to your child.
Shanghai, Shanghai MunicipalityAges 1–18 - NCT07517536Enrolling by invitation
CHT105 treatment for hard-to-treat lupus kidney disease
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
Nanjing, JiangsuAges 18–65 - NCT07378397Enrolling by invitation
MEG brain mapping for epilepsy surgery in children
This study uses a safe brain scan (MEG) to help doctors plan epilepsy surgery for children. It aims to make surgery safer and more precise by mapping key brain areas beforehand.
Birmingham, United KingdomAges 6–15 - NCT07353918Enrolling by invitation
Focused ultrasound for epilepsy treatment
This study tests if low-intensity focused ultrasound can calm overactive brain areas in people with epilepsy. It may offer a new way to reduce seizures without surgery or strong medications.
Roanoke, VirginiaAges 18–85 - NCT07299123Enrolling by invitationPhase 1/Phase 2
Stem cell transplant with cord cells for severe aplastic anemia
This trial tests a new way to treat severe aplastic anemia by combining a stem cell transplant from a half-matched donor with special stem cells from umbilical cord blood. The goal is to help your body make healthy blood cells again.
BeijingAges 6–60 - NCT07257588Enrolling by invitation
Hyperbaric oxygen for severe ulcerative colitis
This study tests whether adding hyperbaric oxygen therapy—breathing pure oxygen in a pressurized chamber—to standard care can help people with a severe flare of ulcerative colitis (a type of inflammatory bowel disease). It may reduce inflammation and speed up recovery.
Xi'an, ShaanxiAges 18 years+ - NCT07210047Enrolling by invitationPhase 1/Phase 2
Study of HuL001 for multiple myeloma that has come back or not responded
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
TaipeiAges 18 years+ - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07003685Enrolling by invitation
Glaucoma drainage device for hard-to-treat glaucoma
This study tests a posterior chamber drainage device for people with glaucoma that is not controlled by eye drops, especially those who have already had cataract surgery. It aims to help lower eye pressure safely and prevent further vision loss.
Ho Chi Minh City, Ho Chi MinhAges 18 years+ - NCT06952764Enrolling by invitation
ECLIPSE: Tracking epilepsy cycles to predict seizures
This trial tests if tracking your brain activity with an implanted device can help predict when seizures might happen. It is for adults who have seizures despite medication and already have the RNS System implanted.
San Francisco, CaliforniaAges 18 years+ - NCT06902792Enrolling by invitationPhase 1
Adebrelimab and trametinib for children with hard-to-treat LCH
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Wenzhou, ZhejiangAges Up to 18 years - NCT06762743Enrolling by invitationPhase 1
Comparing two brivaracetam oral solutions in healthy adults
This study tests whether two different forms of an oral solution of brivaracetam (a seizure medication) have the same effect in the body. Healthy adults take one dose and have blood samples collected—first on an empty stomach, and later after a high-fat meal—to compare how the drug is absorbed.
Nanjing, JiangsuAges 18–55 - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT05859997Enrolling by invitation
CAR-T cell therapy for active autoimmune disease flare-ups
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
Shanghai, Shanghai MunicipalityAges 18–65
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,203 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.